Breaking News

Navin Molecular to Expand Process R&D Capacity

To add new flow synthesis and ozonolysis technologies.

By: Kristin Brooks

Managing Editor, Contract Pharma

Navin Molecular, a CDMO headquartered in India with small molecule development and manufacturing capabilities, is investing $1.2 million to construct a new 1,200-square-meter R&D facility at its site in Dewas, India. The new facility will increase the capacity for laboratory- and kilo-scale process development, as well as enhance analytical development and testing capabilities to support the development and scale up of customer projects.

The new building will have 48 fume hoods for chemical process development and will have specialized technology installed to carry out flow reactions and ozonolysis, as well as the capabilities to safely handle a wide range of hazardous chemistries.

A new kilo-scale lab will be commissioned, with cylindrical vessels up to 100 liters in volume, to mimic conditions on the production plant, and provide flexible capacity to manufacture non-GMP batches of material for preclinical toxicology studies.

Additionally an analytical laboratory will be built, including state-of-the art instrumentation to support method validation and tech transfer of projects. The investment will also upgrade existing labs at Dewas.

Work began on the new facility in December 2024 and it is expected to be completed by May 2025. The expansion will create up to 65 new jobs, doubling the size of the R&D team.

“Robust and thorough process development is crucial to ensure the chance of successful scale up, and customers are looking for partners that are flexible and have the capacity to take on projects with the minimum of delay to meet their demanding timelines,” said Jordi Robinson, Chief Commercial Officer at Navin Molecular. “This expansion will ensure that we can match these expectations, as well as increasing our technology offering through flow chemistry and ozonolysis, ensuring that we can continue to provide the highest quality, cost-effective manufacturing solutions for our customers.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters